Personalis Q2 revenue up 30% to $22.4M; clinical test volume surges 199% YoY

Personalis, Inc.

Clinical test volume of 10,384, up 199% YoY and 33% sequentially; clinical revenue $2.6M (+442% YoY).
Total revenue $22.4M (+30% YoY); pharma testing & other revenue $16.8M (+51%); VA MVP revenue $3.0M (-9%).
Cash and investments $212.7M; secured Medicare coverage for NeXT Personal IO monitoring and neoadjuvant breast cancer.
VICTORI study: NeXT Personal detected 100% of relapses; TRACERx data highlights sub-10 ppm sensitivity in lung cancer.
Due to pending merger with Tempus AI, company will no longer provide financial guidance or hold earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.